Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid.
Alzheimer's disease
T14 peptide
biomarkers
isodendritic core neurons
therapy
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
revised:
21
03
2024
received:
29
01
2024
accepted:
08
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
This perspective offers an alternative to the amyloid hypothesis in the etiology of Alzheimer's disease (AD). We review evidence for a novel signaling mechanism based on a little-known peptide, T14. T14 could drive neurodegeneration as an aberrantly activated process of plasticity selective to interconnecting subcortical nuclei, the isodendritic core, where cell loss starts at the pre-symptomatic stages of the disease. Each of these cell groups has the capacity to form T14, which can stimulate production of p-Tau and β-amyloid, suggestive of an upstream driver of neurodegeneration. Moreover, results in an animal AD model show that antagonism of T14 with a cyclated variant, NBP14, prevents formation of β-amyloid, and restores cognitive function to that of wild-type counterparts. Any diagnostic and/or therapeutic strategy based on T14-NBP14 awaits validation in clinical trials. However, an understanding of this novel signaling system could bring much-needed fresh insights into the progression of cell loss underlying AD. HIGHLIGHTS: The possible primary mechanism of neurodegeneration upstream of amyloid. Primary involvement of selectively vulnerable subcortical nuclei, isodendritic core. Bioactive peptide T14 trophic in development but toxic in context of mature brain. Potential for early-stage biomarker to detect Alzheimer's disease. Effective therapeutic halting neurodegeneration, validated already in 5XFAD mice.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577‐1590.
Theofilas P, Dunlop S, Heinsen H, Grinberg LT. Turning on the light within: subcortical nuclei of the isodentritic core and their role in Alzheimer's disease pathogenesis. J Alzheimers Dis. 2015;46(1):17‐34.
Uematsu M, Nakamura A, Ebashi M, Hirokawa K, Takahashi R, Uchihara T. Brainstem tau pathology in Alzheimer's disease is characterized by increase of three repeat tau and independent of amyloid beta. Acta Neuropathol Commun. 2018;6(1):1.
Leng K, Li E, Eser R, et al. Molecular characterization of selectively vulnerable neurons in Alzheimer's disease. Nat Neurosci. 2021;24(2):276‐287.
Oh JY, Walsh CM, Ranasinghe K, et al. Subcortical neuronal correlates of sleep in neurodegenerative diseases. JAMA Neurol. 2022;79(5):498‐508.
Ramón‐Moliner E, Nauta WJH. The isodendritic core of the brain stem. J Comp Neurol. 1966;126(3):311‐335.
Woolf NJ. Global and serial neurons form A hierarchically arranged interface proposed to underlie memory and cognition. Neuroscience. 1996;74(3):625‐651.
Jacobs HIL, Becker JA, Kwong K, et al. Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. Alzheimers Dement. 2023;19(1):169‐180.
Ehrenberg AJ, Nguy AK, Theofilas P, et al. Quantifying the accretion of hyperphosphorylated tau in the locus coeruleus and dorsal raphe nucleus: the pathological building blocks of early Alzheimer's disease. Neuropathol Appl Neurobiol. 2017;43(5):393‐408.
Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960‐969.
Flores‐Aguilar L, Hall H, Orciani C, et al. Early loss of locus coeruleus innervation promotes cognitive and neuropathological changes before amyloid plaque deposition in a transgenic rat model of Alzheimer's disease. Neuropathol Appl Neurobiol. 2022;48(6):e12835.
Ghosh A, Torraville SE, Mukherjee B, et al. An experimental model of Braak's pretangle proposal for the origin of Alzheimer's disease: the role of locus coeruleus in early symptom development. Alzheimers Res Ther. 2019;11(1):59.
Garcia‐Ratés S, Greenfield S. When a trophic process turns toxic: alzheimer's disease as an aberrant recapitulation of a developmental mechanism. Int J Biochem Cell Biol. 2022;149:106260.
Day T, Greenfield SA. A non‐cholinergic, trophic action of acetylcholinesterase on hippocampal neurones in vitro: molecular mechanisms. Neuroscience. 2002;111(3):649‐656.
Layer PG. Cholinesterases preceding major tracts in vertebrate neurogenesis. Bioessays. 1990;12(9):415‐420.
Stewart TA, Davis FM. An element for development: calcium signaling in mammalian reproduction and development. Biochim Biophys Acta Mol Cell Res. 2019;1866(7):1230‐1238.
Ranglani S, Ashton A, Mahfooz K, et al. A novel bioactive peptide, T14, selectively activates mTORC1 signalling: therapeutic implications for neurodegeneration and other rapamycin‐sensitive applications. Int J Mol Sci. 2023;24(12):9961.
García‐Ayllón M‐S. Revisiting the role of acetylcholinesterase in Alzheimer's disease: cross‐talk with P‐tau and beta‐Amyloid. Front Mol Neurosci. 2011;4:22.
Butcher LL, Woolf NJ. Neurotrophic agents may exacerbate the pathologic cascade of Alzheimer's disease. Neurobiol Aging. 1989;10(5):557‐570.
Arendt T, Brückner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development–a study of molecular forms. Neurochem Int. 1992;21(3):381‐396.
Campanari M‐L, García‐Ayllón M‐S, Blazquez‐Llorca L, Luk WKW, Tsim K, Sáez‐Valero J. Acetylcholinesterase protein level is preserved in the Alzheimer's brain. J Mol Neurosci. 2014;53(3):446‐453.
Cortés‐Gómez M‐Á, Llorens‐Álvarez E, Alom J, et al. Tau phosphorylation by glycogen synthase kinase 3beta modulates enzyme acetylcholinesterase expression. J Neurochem. 2021;157(6):2091‐2105.
Henderson Z, Greenfield SA. Ultrastructural localization of acetylcholinesterase in substantia nigra: a comparison between rat and guinea pig. J Comp Neurol. 1984;230(2):278‐286.
Ranglani S, Hasan S, Komorowska J, et al. A novel peptide driving neurodegeneration appears exclusively linked to the α7 nicotinic acetylcholine receptor. Mol Neurobiol. 2024.
Seguela P, Wadiche J, Dineley‐Miller K, Dani J, Patrick J. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci. 1993;13(2):596‐604.
Taylor P, Radić Z, Kreienkamp H‐J, et al. Expression and ligand specificity of acetylcholinesterase and the nicotinic receptor: a tale of two cholinergic sites. Biochem Soc Trans. 1994;22(3):740‐745.
Greenfield SA, Ferrati G, Coen CW, et al. Characterization of a bioactive peptide T14 in the human and rodent substantia nigra: implications for neurodegenerative disease. Int J Mol Sci. 2022;23(21):13119.
Lee C‐H, Hung S‐Y. Physiologic functions and therapeutic applications of alpha7 nicotinic acetylcholine receptor in brain disorders. Pharmaceutics. 2022;15(1):31.
Counts SE, He B, Che S, et al. Alpha7 nicotinic receptor up‐regulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol. 2007;64(12):1771‐1776.
Yu W, Mechawar N, Krantic S, Chabot J‐G, Quirion R. Upregulation of astrocytic α7 nicotinic receptors in Alzheimer's disease brain‐ possible relevant to amyloid pathology. Mol Neurodegeneration. 2012;7:O7‐O7.
Svedberg MM, Svensson A‐L, Johnson M, et al. Upregulation of neuronal nicotinic receptor subunits alpha4, beta2, and alpha7 in transgenic mice overexpressing human acetylcholinesterase. J Mol Neurosci. 2002;18(3):211‐222.
Graur A, Sinclair P, Schneeweis AK, Pak DT, Kabbani N. The human acetylcholinesterase C‐terminal T30 peptide activates neuronal growth through alpha 7 nicotinic acetylcholine receptors and the mTOR pathway. Sci Rep. 2023;13(1):11434.
Taly A, Corringer P‐J, Guedin D, Lestage P, Changeux J‐P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009;8(9):733‐750.
Greenfield SA, Cole GM, Coen CW, et al. A novel process driving Alzheimer's disease validated in a mouse model: therapeutic potential. Alzheimers Dement (N Y). 2022;8(1):e12274.
Oakley H, Cole SL, Logan S, et al. Intraneuronal beta‐amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129‐10140.
Mehta NH, Sherbansky J, Kamer AR, et al. The brain‐nose interface: a potential cerebrospinal fluid clearance site in humans. Front Physiol. 2021;12:769948.
Kim YH, Lee S‐M, Cho S, et al. Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer's disease. Sci Rep. 2019;9(1):4966.
Rocha S, Ratés SG, Moswete T, et al. A novel peptide ‘T14’ reflects age and photo‐aging in human skin. Aging. 2023;15(12):5279‐5289.
Castanedo‐Cazares JP, Rodriguez‐Leyva I. Skin biomarkers for neurodegenerative disease: a future perspective. Neurodegener Dis Manag. 2015;5(6):465‐467.
Sinclair E, Trivedi DK, Sarkar D, et al. Metabolomics of sebum reveals lipid dysregulation in Parkinson's disease. Nat Commun. 2021;12(1):1592.
Bakhtiari S, Moghadam NB, Ehsani M, et al. Can salivary acetylcholinesterase be a diagnostic biomarker for Alzheimer? J Clin Diagn Res. 2017;11(1):ZC58‐ZC60.
Van Dyck CH, Swanson CJ, Aisen P. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9‐21.
Bateman RJ, Smith J, Donohue MC, et al. Two phase 3 trials of gantenerumab in early Alzheimer's disease. N Engl J Med. 2023;389(20):1862‐1876.
Garcia‐Ratés S, Morrill P, Tu H, et al. (I) Pharmacological profiling of a novel modulator of the alpha7 nicotinic receptor: blockade of a toxic acetylcholinesterase‐derived peptide increased in Alzheimer brains. Neuropharmacology. 2016;105:487‐499.
Giacobini E, Cuello AC, Fisher A. Reimagining cholinergic therapy for Alzheimer's disease. Brain. 2022;145(7):2250‐2275.
Ranglani S, Hasan S, Mahfooz K, Gordon J, Garcia‐Rates S, Greenfield S. Antagonism of a key peptide ‘T14’ driving neurodegeneration: evaluation of a next generation therapeutic. Biomed Pharmacother. 2023;167:115498.
Dong X‐X, Wang Y, Qin Z‐H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379‐387.
Dickie BGM, Holmes C, Greenfield SA. Neurotoxic and neurotrophic effects of chronic N‐methyl‐D‐aspartate exposure upon mesencephalic dopaminergic neurons in organotypic culture. Neuroscience. 1996;72(3):731‐741.
Eimerl S, Schramm M. The quantity of calcium that appears to induce neuronal death. J Neurochem. 1994;62(3):1223‐1226.
Andrés‐Benito P, Fernández‐Dueñas V, Carmona M. Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. Neuropathol Appl Neurobiol. 2017;43(5):373‐392.
Liguori I, Russo G, Curcio F. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018;13:757‐772.
Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta‐deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791‐1800.